نتائج البحث - "Rodríguez-Moreno, Juan Francisco"

1

دورية أكاديمية

Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.

المؤلفون: Schoenfeld, Adam J, Lee, Sylvia M, Doger de Speville, Bernard, Gettinger, Scott N, Hafliger, Simon, Sukari, Ammar, Papa, Sophie, Rodriguez-Moreno, Juan Francisco, Graf Finckenstein, Friedrich, Fiaz, Rana, Catlett, Melissa, Chen, Guang, Qi, Rongsu, Masteller, Emma L, Gontcharova, Viktoria, He, Kai

المصدر: Schoenfeld, Adam J; Lee, Sylvia M; Doger de Speville, Bernard; Gettinger, Scott N; Hafliger, Simon; Sukari, Ammar; Papa, Sophie; Rodriguez-Moreno, Juan Francisco; Graf Finckenstein, Friedrich; Fiaz, Rana; Catlett, Melissa; Chen, Guang; Qi, Rongsu; Masteller, Emma L; Gontcharova, Viktoria; He, Kai (2024). Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. (In Press). Cancer discovery American Association for Cancer Research 10.1158/2159-8290.CD-23-1334

مصطلحات موضوعية: 610 Medicine & health

وصف الملف: application/pdf

العلاقة: https://boris.unibe.ch/195558Test/

الإتاحة: https://doi.org/10.1158/2159-8290.CD-23-1334Test
https://boris.unibe.ch/195558/1/cd-23-1334.pdfTest
https://boris.unibe.ch/195558Test/

View record in BASE

2

دورية أكاديمية

Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution

المساهمون: Novartis, Instituto de Salud Carlos III, European Research Council, Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), Nafarroako Gobernua

مصطلحات موضوعية: Simvastatin, COVID19, SARS-Cov-2, Clinical trial, Cytokine storm, Ruxolitinib

وصف الملف: application/pdf

العلاقة: #PLACEHOLDER_PARENT_METADATA_VALUE#; info:eu-repo/grantAgreement/EC/H2020/851255; info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/CEX2021-001164-M; Publisher's version; García-Donas, Jesús; Martínez-Urbistondo, Diego; Velázquez Kennedy, Kyra; Villares, Paula; Barquin, Arántzazu; Domínguez, Andrea; Rodríguez-Moreno, Juan Francisco; Caro, Elena; Suárez del Villar, Rafael; Nistal-Villan, Estanislao; Yagüe, Mónica; Ortiz, Maria; Barba, Maria; Ruiz-Llorente, Sergio; Quiralte, Miguel; Zanin, Massimiliano; Rodríguez, Cristina; Navarro, Paloma; Berraondo, Pedro; Madurga, Rodrigo; 2023; DataSheet_1_Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.pdf [Dataset]; Figshare; https://doi.org/10.3389/fimmu.2023.1156603.s001Test; Navarro, Paloma; Berraondo, Pedro; Madurga, Rodrigo; 2023; Table_1_Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.xlsx [Dataset]; Figshare; https://doi.org/10.3389/fimmu.2023.1156603.s002Test; https://doi.org/10.3389/fimmu.2023.1156603Test; Sí; Frontiers in Immunology 14: 1156603 (2023); CEX2021-001164-M; http://hdl.handle.net/10261/352169Test; http://dx.doi.org/10.13039/100004336Test; http://dx.doi.org/10.13039/501100011033Test; http://dx.doi.org/10.13039/501100000781Test; http://dx.doi.org/10.13039/501100004587Test; http://dx.doi.org/10.13039/501100004837Test; 2-s2.0-85159553059; https://api.elsevier.com/content/abstract/scopus_id/85159553059Test